Quanterix Expands Kevin Hrusovsky’s Role To CEO
Lexington, MA – March 4, 2015 Quanterix Corporation, a leader in ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Chief Executive Officer (“CEO”). Mr. Hrusovsky will continue to serve as Executive Chairman of its Board of Directors.
“I am thrilled to have Kevin join the Quanterix team as CEO,” said Dr. David Walt, scientific founder and director of both Quanterix and Illumina. “Kevin’s experience and success with Caliper and PerkinElmer position Quanterix for scale-up to full commercialization of the transformative Simoa technology. I am excited to work with Kevin and his team to propel Quanterix to become the dominant company in ultrasensitive protein assays for both research and diagnostic applications.”
Kevin Hrusovsky brings over twenty years of experience in life science and diagnostics industries with a strong track record for innovation and commercializing disruptive technologies. Prior to joining Quanterix, he was President of Life Sciences and Technologies at PerkinElmer, CEO of Caliper Life Sciences (sold to PerkinElmer); and CEO of Zymark (sold to Caliper). Through a series of strategic acquisitions and divestitures, Mr. Hrusovsky succeeded in building substantial value, while providing researchers around the world with cutting-edge enabling tools. “As a significant investor in Caliper (CALP), we have seen first-hand the remarkable operational, strategic and leadership strength that Kevin brings to the office of the CEO at Quanterix,” said Keith Crandell, Co-Founder and Managing Director at ARCH Venture Partners, one of the company’s lead investors. “Quanterix has by far the broadest and most powerful ultra-sensitive assay technology, and is poised for tremendous commercial growth. Under Kevin’s leadership, Quanterix, will fundamentally improve life sciences research and diagnostics. We are delighted that Kevin is the driving force in the commercial stage.”
Prior to joining Zymark, Mr. Hrusovsky was President of FMC Corporation’s Pharmaceuticals and International Agricultural Products, and held management positions at E.I. DuPont de Nemours. He currently serves on the Board of Directors of Cell Signaling, 908 Devices, SynapDX and Solect Energy.
“I am honored to be part of the Quanterix team, and believe we are poised for compelling growth and value creation,” said Mr. Hrusovsky. “Since launching our ‘bleed to read’ Simoa instrument and Accelerator services for RUO applications and establishing a comprehensive partnership with bioMérieux for IVD applications, we have seen a flurry of studies across all the important therapeutic categories demonstrating the large potential for this technology to transform healthcare. We are excited about the strength of our team, partners, investors and early collaborators and are exploring ways to accelerate our ascent into a world-class leader in life science and diagnostics.”
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
Nikki Festa & Caitlyn Keating
Share this page